Published in J Virol Methods on November 01, 1986
International uniform response criteria for multiple myeloma. Leukemia (2006) 17.78
Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome. Proc Natl Acad Sci U S A (1997) 5.37
Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells. Proc Natl Acad Sci U S A (1998) 5.37
The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J (2000) 3.52
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia (2008) 3.41
Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J (1998) 3.01
Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J (1997) 2.87
Borna disease: a persistent virus infection of the central nervous system. Prog Med Virol (1988) 2.83
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia (2007) 2.76
Genomic organization of Borna disease virus. Proc Natl Acad Sci U S A (1994) 2.74
B-cell proliferation and induction of early G1-regulating proteins by Epstein-Barr virus mutants conditional for EBNA2. EMBO J (1995) 2.51
Human origin recognition complex binds to the region of the latent origin of DNA replication of Epstein-Barr virus. EMBO J (2001) 2.46
Immortalization of human B lymphocytes by a plasmid containing 71 kilobase pairs of Epstein-Barr virus DNA. J Virol (1995) 2.45
Borna disease virus, a negative-strand RNA virus, transcribes in the nucleus of infected cells. Proc Natl Acad Sci U S A (1992) 2.44
Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade. EMBO J (1997) 2.38
Repetitive sequences in complete and defective genomes of Herpesvirus saimiri. J Virol (1975) 2.36
Borna disease virus genome transcribed and expressed in psychiatric patients. Nat Med (1995) 2.30
The challenge of biosimilars. Ann Oncol (2007) 2.28
The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer (1993) 2.23
Identification of a common antigen of herpes simplex virus bovine herpes mammillitis virus, and B virus. J Virol (1978) 2.16
Interleukin-6 is a prognostic factor in multiple myeloma. Blood (1991) 2.16
Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. EMBO J (1999) 2.09
A viro-psycho-immunological disease-model of a subtype affective disorder. Pharmacopsychiatry (1998) 2.08
Infectious Epstein-Barr virus lacking major glycoprotein BLLF1 (gp350/220) demonstrates the existence of additional viral ligands. J Virol (2000) 2.04
Glycoprotein gp110 of Epstein-Barr virus determines viral tropism and efficiency of infection. Proc Natl Acad Sci U S A (2002) 1.99
A transcription factor with homology to the AP-1 family links RNA transcription and DNA replication in the lytic cycle of Epstein-Barr virus. EMBO J (1993) 1.96
Identification of a protein essential for replication of porcine circovirus. J Gen Virol (1998) 1.92
Characterization of LMP-1's association with TRAF1, TRAF2, and TRAF3. J Virol (1997) 1.90
Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood (1998) 1.90
The replication origin region of Escherichia coli: nucleotide sequence and functional units. Gene (1983) 1.87
Physicochemical properties of the DNA of herpes viruses. Biochim Biophys Acta (1972) 1.86
First isolates of infectious human Borna disease virus from patients with mood disorders. Mol Psychiatry (1996) 1.83
cis-acting elements in the lytic origin of DNA replication of Epstein-Barr virus. J Virol (1993) 1.80
A simple method for measuring red cell deformability in models of the microcirculation. Blut (1973) 1.75
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia (2012) 1.74
Mapping and characterization of the origin of DNA replication of porcine circovirus. J Virol (1997) 1.71
Sequence conservation in field and experimental isolates of Borna disease virus. J Virol (1994) 1.67
Detection of new DNA polymerase genes of known and potentially novel herpesviruses by PCR with degenerate and deoxyinosine-substituted primers. Virus Genes (1999) 1.65
Amantadine and human Borna disease virus in vitro and in vivo in an infected patient with bipolar depression. Lancet (1997) 1.62
Persistent, tolerant or subacute infection in Borna disease virus-infected rats. J Gen Virol (1983) 1.62
Cerebrovascular tone rather than intracranial pressure determines the effective downstream pressure of the cerebral circulation in the absence of intracranial hypertension. J Neurosurg Anesthesiol (2000) 1.61
Clp-mediated proteolysis in Gram-positive bacteria is autoregulated by the stability of a repressor. EMBO J (2001) 1.61
Borna disease--neuropathology and pathogenesis. Curr Top Microbiol Immunol (1995) 1.59
Borna disease virus-specific antibodies in patients with HIV infection and with mental disorders. Lancet (1988) 1.57
Episomal and integrated copies of Epstein-Barr virus coexist in Burkitt lymphoma cell lines. J Virol (1993) 1.56
Molecular virology of Epstein-Barr virus. Philos Trans R Soc Lond B Biol Sci (2001) 1.54
Epstein-Barr virus latent membrane protein (LMP1) is not sufficient to maintain proliferation of B cells but both it and activated CD40 can prolong their survival. EMBO J (1996) 1.53
Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin-10. Blood (1997) 1.47
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.47
Activation of oriLyt, the lytic origin of DNA replication of Epstein-Barr virus, by BZLF1. Virology (1996) 1.46
Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer (2010) 1.46
Latent Marek's disease virus can be activated from its chromosomally integrated state in herpesvirus-transformed lymphoma cells. EMBO J (1993) 1.44
Genome sequence of bovine herpesvirus 4, a bovine Rhadinovirus, and identification of an origin of DNA replication. J Virol (2001) 1.44
TRAF6 is a critical mediator of signal transduction by the viral oncogene latent membrane protein 1. EMBO J (2001) 1.42
Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia (2008) 1.42
Immunologic and genetic relationship between herpes simplex virus and bovine herpes mammillitis virus. Intervirology (1974) 1.41
Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol (2000) 1.39
Modeling of treatment response to erythropoiesis-stimulating agents as a function of center- and patient-related variables: results from the Anemia Cancer Treatment (ACT) study. Ann Oncol (2009) 1.39
Structure and role of the terminal repeats of Epstein-Barr virus in processing and packaging of virion DNA. J Virol (1995) 1.35
Specificity of cleavage in replicative-form DNA of bovine herpesvirus 1. J Virol (1988) 1.34
Borna disease in ostriches. Vet Rec (1993) 1.34
Studies on the relatedness of herpes viruses through DNA-RNA hybridization. Biochim Biophys Acta (1972) 1.31
Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol (2012) 1.31
Activation of the Epstein-Barr virus transcription factor BZLF1 by 12-O-tetradecanoylphorbol-13-acetate-induced phosphorylation. J Virol (1998) 1.30
Immunoprecipitation of herpes simplex virus type 1 antigens with different antisera and human cerebrospinal fluids. Arch Virol (1977) 1.30
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia (2009) 1.29
Behavior alterations in tree shrews (Tupaia glis, Diard 1820) induced by Borna disease virus. Med Microbiol Immunol (1978) 1.29
[Borna virus infection (Borna disease) in naturally and experimentally infected animals: its significance for research and practice]. Tierarztl Prax (1985) 1.29
Analysis of herpes simplex virus type 1 antigens exposed on the surface of infected tissue culture cells. Virology (1978) 1.28
Status of Marek's disease virus in established lymphoma cell lines: herpesvirus integration is common. J Virol (1993) 1.27
Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer (1994) 1.25
The characterization of Varicella-zoster virus DNA. J Gen Virol (1972) 1.23
Adaptation of Borna disease virus to the mouse. J Gen Virol (1984) 1.23
Human infections with Borna disease virus: seroprevalence in patients with chronic diseases and healthy individuals. J Med Virol (1992) 1.22
Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia (2006) 1.22
Immortalization of human primary B lymphocytes in vitro with DNA. Proc Natl Acad Sci U S A (1995) 1.22
Cellular transcription factors recruit viral replication proteins to activate the Epstein-Barr virus origin of lytic DNA replication, oriLyt. EMBO J (1999) 1.21
LMP1 signal transduction differs substantially from TNF receptor 1 signaling in the molecular functions of TRADD and TRAF2. EMBO J (1999) 1.21
Increase of virus yields and releases of Borna disease virus from persistently infected cells. Virus Res (1985) 1.20
Persistent infection of Epstein-Barr virus-positive B lymphocytes by human herpesvirus 8. J Virol (1998) 1.19
Natural Borna disease in domestic animals others than horses and sheep. Zentralbl Veterinarmed B (1993) 1.18
The ionic properties of the filamentous bacteriophages Pf1 and fd. J Biol Chem (1986) 1.18
[Autoimmune phenomena in D-penicillamine therapy]. Acta Med Austriaca (1975) 1.17
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia (2011) 1.17
Isolation and characterization of a 14500 molecular weight protein from brains and tissue cultures persistently infected with borna disease virus. J Gen Virol (1985) 1.17
Small in-frame deletions and missense mutations in CADASIL: 3D models predict misfolding of Notch3 EGF-like repeat domains. Eur J Hum Genet (2000) 1.17
A first-generation packaging cell line for Epstein-Barr virus-derived vectors. Proc Natl Acad Sci U S A (1999) 1.16
Interferon-alpha stimulates the hypothalamic-pituitary-adrenal axis in vivo and in vitro. Neuroendocrinology (1993) 1.16
Learning deficiencies in Borna disease virus-infected but clinically healthy rats. Biol Psychiatry (1989) 1.15
Sequence characterization of human Borna disease virus. Virus Res (1996) 1.15
Inhibition of herpes virus-induced cell fusion by concanavalin A, antisera, and 2-deoxy-D-glucose. J Virol (1974) 1.14
Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone (1996) 1.14
Borna disease in rhesus monkeys as a models for uveo-cerebral symptoms. J Med Virol (1981) 1.13